A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Clinical trial NCT03310619 · COMPLETED

Trial details

NCT number: NCT03310619
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular

Start date: 2017-12-20
Primary completion: 2023-02-15
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.